[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Books, Journals, New Media
February 4, 2004

Cancer Cure

Author Affiliations

Books, Journals, New Media Section Editor: Harriet S. Meyer, MD, Contributing Editor, JAMA; David H. Morse, MS, University of Southern California, Norris Medical Library, Journal Review Editor.

JAMA. 2004;291(5):626-627. doi:10.1001/jama.291.5.626

In 1998, Neil Ruzic, a scientist, inventor, science publisher, and journalist, was diagnosed with mantle cell lymphoma (MCL), a particularly deadly form of non-Hodgkin lymphoma of which it comprises 5% to 10%. Although MCL appears to be phenotypically indolent (and was previously classified as intermediate lymphocytic or small–clear cell lymphoma), it behaves aggressively. It is characterized by a unique chromosomal abnormality, t(11;14) (q13;q32), which approximates the bcl-1 oncogene at the 11q13 locus to the immunoglobulin heavy-chain locus at 14q32. This translocation leads to overexpression of cyclin D1, which regulates the transition from the G1 to S phase of the cell cycle.

First Page Preview View Large
First page PDF preview
First page PDF preview